In short, anti-tumour effector cells, including CD4+ helper T cells and CD8+ cytotoxic T cells, in addition to the ratio of CD8+ cytotoxic to FOXP3+ T regulatory (Tregs), are associated with better patient prognosis and response [64]. This evidence concerns the gene CD8A and neoplasm.